Company Profile
Edding Genor provides the research, development, manufacturing, and distribution of biopharmaceutical products globally. The company offers GB491, a differentiated CDK4/6 inhibitor for advanced or metastatic breast cancer.
Its portfolio also includes GB261, a novel CD3/CD20 bispecific antibody which is in Phase III clinical trial for autoimmune diseases, and GB263T and GB268, tri-specific antibody candidates which are Phase I clinical trial Vancocin for multidrug-resistant gram-positive bacteria.
Its portfolio also includes Ceclor for mild to moderate community-acquired bacterial infections in children, Yirui Ping for nebulized inhalation therapy, Vascepa for cardiovascular risk reduction, Mulpleta for reducing bleeding risk, Jing Zhu Da for breast cancer treatment, Recormon for CRA indication, and three siRNA candidates for chronic disease treatment
Entinostat and lerociclib hydrochloride tablets. Additionally, it is involved in marketing, commercialization, and trading of pharmaceutical products. Its portfolio also includes R&D of respiratory products, and consultancy and promotion services.
Its products are used in oncology, autoimmune, cardiovascular, respiratory, and anti-infective therapeutic areas. Founded in 2001, Edding Genor is headquartered in Zhuhai, China.